Description
Favipiravir 200 mg is the first oral antiviral medication under the trade name FabiFlu for the treatment of mild to severe COVID-19 cases, Glenmark Pharmaceutical launch this medication. This medicine shows 80-88% efficacy in global clinical trials and it is currently used in Japan and UAE for the Covid-19 treatment.
On 19 June 2020, India drug regulator approved Fabiflu for oral administration in India.